| Literature DB >> 35733678 |
Liju Fan1,2, Jing An2, Jin Gao3, Yanjun Cui1, Zhanjun Dong1,2.
Abstract
A novel extraction procedure was developed using polystyrene (PS) nanofibers as a solid-phase extraction sorbent to collect atypical antipsychotics (AAPs) from human plasma. The extraction targets were then monitored by ultra high performance liquid chromatography with an ultraviolet detector system. Parameters affecting extraction efficiency such as fiber packing amount, wash solution, and eluted solvent were investigated. Under optimized conditions, the linear range of seven AAPs was 1-50 μgmL-1 (R 2 > 0.996). Inter-day and intra-day relative standard deviations were less than 15.1%, and relative error varied from -17.1% to 12.0%. Furthermore, 50.5-79.3% extraction recoveries were obtained. The lower limit of quantification was 1 μg mL-1, and detection limit was 0.5 μg mL-1. The method developed in this study may be applied to simultaneous quantification of seven AAPs in human plasma due to its simplicity, selectivity, and efficiency. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 35733678 PMCID: PMC9155176 DOI: 10.1039/d2ra02457h
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Schematic representation of PS-SPE device.
Fig. 2Structure of seven analytes.
Fig. 3SEM images of porous structure of the nanofiber packing. Low-resolution (A), high-resolution (B).
Fig. 4Influence of packing quantity of polystyrene nanofibers.
Fig. 5Influence of eluent volume (n = 3).
Fig. 6Influence of washing solution (n = 3). (A) represents the eluted substances by using washing solutions, (B) represents the extraction efficiency of seven analytes after washing. 2.5% (2.5% aqueous methanol solution), 5% (5% aqueous methanol solution), 10% (10% aqueous methanol solution).
Fig. 7Typical chromatograms of seven analytes (wavelength = 280 nm). (A) The standard solution at 10 μg mL; (B) plasma sample spiked with the analytes at 10 μg mL; (C) blank plasma sample. (1) Olanzapine; (2) paliperidone; (3) risperidone; (4) clozapine; (5) quetiapine; (6) ziprasidone; (7) aripiprazole.
Calibration curves, LODs and LOQs of the seven analytes in human plasma samples
| Analytes | Regression equation | Linear range (μg mL−1) |
| LLOQs (μg mL−1) | LODs (μg mL−1) |
|---|---|---|---|---|---|
| Aripiprazole |
| 1–50 | 0.9978 | 1 | 0.5 |
| Paliperidone |
| 1–50 | 0.9954 | 1 | 0.5 |
| Clozapine |
| 1–50 | 0.9971 | 1 | 0.5 |
| Ziprasidone |
| 1–50 | 0.9984 | 1 | 0.5 |
| Olanzapine |
| 1–50 | 0.9961 | 1 | 0.5 |
| Quetiapine |
| 1–50 | 0.9959 | 1 | 0.5 |
| Risperidone |
| 1–50 | 0.9967 | 1 | 0.5 |
Precision, relative error and extraction efficiency of the seven analytes
| Analytes | Intra-day ( | Inter-day ( | Extraction efficiency | ||||
|---|---|---|---|---|---|---|---|
| Mean ± SD (%) | RE (%) | RSD (%) | Mean ± SD (%) | RE (%) | RSD (%) | ||
| Aripiprazole | 2.7 ± 0.1 | 8.0 | 3.7 | 2.7 ± 0.2 | 8.0 | 7.4 | 51.4 |
| 26.6 ± 2.1 | 6.4 | 7.8 | 27.2 ± 1.8 | 8.8 | 6.6 | 53.8 | |
| 48.6 ± 5.4 | 8.0 | 11.1 | 49.4 ± 4.5 | 9.8 | 9.1 | 50.5 | |
| Paliperidone | 2.8 ± 0.1 | 12.0 | 3.6 | 2.7 ± 0.1 | 8.0 | 3.7 | 72.4 |
| 21.6 ± 1.8 | −13.6 | 8.3 | 23.9 ± 3.4 | −4.4 | 14.2 | 78.2 | |
| 37.3 ± 0.9 | −17.1 | 2.4 | 39.7 ± 6.0 | −11.8 | 15.1 | 74.2 | |
| Clozapine | 2.8 ± 0.1 | 12.0 | 3.6 | 2.6 ± 0.2 | 4.0 | 7.7 | 62.9 |
| 24.8 ± 2.0 | −0.8 | 8.1 | 26.0 ± 2.3 | 4.0 | 8.8 | 73.3 | |
| 43.3 ± 0.9 | −3.8 | 2.1 | 43.9 ± 5.9 | −2.4 | 13.4 | 65.4 | |
| Ziprasidone | 2.8 ± 0.1 | 12.0 | 3.6 | 2.8 ± 0.1 | 12.0 | 3.6 | 55.0 |
| 26.5 ± 1.3 | 6.0 | 4.9 | 26.8 ± 1.2 | 7.2 | 4.5 | 66.1 | |
| 47.1 ± 5.1 | 4.7 | 10.8 | 45.1 ± 5.1 | 0.2 | 11.3 | 58.1 | |
| Olanzapine | 2.5 ± 0.1 | 0.0 | 4.0 | 2.4 ± 0.1 | −4.0 | 4.2 | 68.3 |
| 23.6 ± 3.1 | −5.6 | 13.1 | 24.8 ± 3.3 | −0.8 | 13.3 | 70.1 | |
| 37.3 ± 1.3 | −17.1 | 3.5 | 39.4 ± 5.4 | −12.4 | 13.7 | 72.4 | |
| Quetiapine | 2.8 ± 0.1 | 12.0 | 3.6 | 2.7 ± 0.1 | 8.0 | 3.7 | 69.1 |
| 23.3 ± 0.9 | −6.8 | 3.9 | 25.4 ± 2.5 | 1.6 | 9.8 | 68.7 | |
| 40.9 ± 1.0 | −9.1 | 2.4 | 42.3 ± 5.4 | −6.0 | 12.8 | 79.3 | |
| Risperidone | 2.8 ± 0.1 | 12.0 | 3.6 | 2.7 ± 0.1 | 8.0 | 3.7 | 72.3 |
| 24.1 ± 2.6 | −3.6 | 10.8 | 25.4 ± 3.0 | 1.6 | 11.8 | 79.9 | |
| 39.6 ± 1.7 | −12.0 | 4.3 | 43.6 ± 6.9 | −3.1 | 15.8 | 71.5 | |
Stability of seven drugs in human plasma under various storage conditions (n = 5)
| Analytes | Spiked conc. (μg mL−1) | Post-preparation stability (4 °C for 24 h) | Long-term stability (−20 °C, 7 days) | Freeze–thaws (−20 °C to 25 °C) | |||
|---|---|---|---|---|---|---|---|
| Mean ± SD | RSD (%) | Mean ± SD | RSD (%) | Mean ± SD | RSD (%) | ||
| Aripiprazole | 2.5 | 2.7 ± 0.3 | 11.1 | 2.4 ± 0.2 | 8.3 | 2.5 ± 0.2 | 8.0 |
| 45 | 46.3 ± 1.9 | 4.1 | 52.7 ± 1.1 | 2.1 | 44.0 ± 2.1 | 4.8 | |
| Paliperidone | 2.5 | 2.8 ± 0.1 | 3.6 | 2.6 ± 0.3 | 11.5 | 2.4 ± 0.4 | 16.7 |
| 45 | 44.2 ± 6.0 | 13.6 | 39.8 ± 14.9 | 37.4 | 41.1 ± 6.4 | 15.6 | |
| Clozapine | 2.5 | 2.6 ± 0.1 | 3.9 | 2.9 ± 0.1 | 3.4 | 2.6 ± 0.2 | 7.7 |
| 45 | 44.7 ± 3.7 | 8.3 | 48.4 ± 3.3 | 6.8 | 45.5 ± 4.4 | 9.7 | |
| Ziprasidone | 2.5 | 2.9 ± 0.5 | 17.2 | 2.2 ± 0.2 | 9.1 | 2.6 ± 0.3 | 11.5 |
| 45 | 48.2 ± 4.7 | 9.8 | 50.5 ± 1.1 | 2.2 | 44.9 ± 3.5 | 7.8 | |
| Olanzapine | 2.5 | 2.4 ± 0.3 | 12.5 | 2.6 ± 0.3 | 11.5 | 2.0 ± 0.5 | 25.0 |
| 45 | 43.7 ± 6.0 | 13.7 | 31.1 ± 2.5 | 8.0 | 44.4 ± 5.4 | 12.3 | |
| Quetiapine | 2.5 | 2.7 ± 0.1 | 3.7 | 2.7 ± 0.2 | 7.4 | 2.6 ± 0.1 | 3.8 |
| 45 | 44.6 ± 4.6 | 10.3 | 48.5 ± 7.0 | 14.4 | 46.1 ± 4.9 | 10.6 | |
| Risperidone | 2.5 | 2.7 ± 0.2 | 7.4 | 2.8 ± 0.1 | 3.6 | 2.6 ± 0.1 | 3.9 |
| 45 | 46.1 ± 6.2 | 13.4 | 50.2 ± 7.1 | 14.1 | 45.5 ± 5.1 | 11.2 | |
Comparison of the reported methods with the proposed method for the determination of AAPs in human plasma
| Analytes | Sample volume | LOQ | Extraction recovery | Method | Ref. |
|---|---|---|---|---|---|
| Clozapine, lanzapine, quetiapine | 500 μL | 2.0 ng mL−1 | ≥0.79 | SPE-GC-MS/MS |
|
| Amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone sulpiride | 200 μL | 1.0–5.0 ng mL−1 | ≥0.67 | LLE-LC-MS/MS |
|
| Amisulpride, olanzapine, aripiprazole, paliperidone ziprasidone | 20 μL | 0.1–9.0 ng mL−1 | ≥0.86 | PP-UPLC-MS/MS |
|
| Olanzapine, clozapine, quetiapine | — | 1.25–40 ng mL−1 | ≥0.93 | Column-switching -HPLC-UV |
|
| Olanzapine, quetiapine, clozapine, haloperidol, chlorpromazine | 200 μL | 0.05-1 ng mL−1 | — | MEPS LC-MS/MS |
|
| Clozapine, risperidone, quetiapine, aripiprazole, olanzapine | 450 μL | 0.5–1.0 ng mL−1 | ≥0.51 | LLE-LC-MS/MS |
|
| Risperidone, clozapine, quetiapine, aripiprazole | 1500 μL | 4.7–18.8 ng mL−1 | ≥0.80 | SPE-HPLC-DAD |
|
| Olanzapine, risperidone, paliperidone, clozapine, quetiapine, ziprasidone aripiprazole | 90 μL | 1.0 μg mL−1 | ≥0.58 | PS-SPE-UPLC-UV | This paper |